

Excellence and Innovation
in patients care

www.recherche.unicancer.fr/en





Research is at the heart of Unicancer's action. In recent years, cancer research has proven to be a formidable field of therapeutic, technological and organisational innovation.

Pr. Jean-Yves Blay – Unicancer Président



Innovative by nature, the Centres in our network have always been at the forefront of the fight against cancer to improve patient care, by ensuring rapid access to innovations in care and research.

Sophie Beaupère – Unicancer General Director



THE UNICANCER NETWORK, A MAJOR PLAYER IN ONCOLOGY RESEARCH

The health crisis has demonstrated the need for an agile health system and a supportive environment for research and innovation.

Although the development of science, research and new technologies now makes it possible to better detect, treat and live with cancer, it remains the leading cause of death in France.

This is why cancer research is one of the foundations of the Unicancer network's ambition, which is to do everything possible to provide patients with ever earlier detection and ever more innovative and personalised treatments.

Unicancer is more than 22,000 highly qualified women and men, united, committed and driven by a common and ambitious objective: to cure cancer.

100%
dedicated to the fight
against cancer




GCS* UNICANCER RESEARCH

As the leading academic sponsor of clinical trials in oncology in Europe, Unicancer plays a leading role in cancer research.

Driven by strong values and ambitions, we have always defended the key levers of **our strategy**:

- **Intensify** prevention and screening
- **Improve** the quality of life of patients
- **Develop** artificial intelligence and data science
- **Increase** research programmes in cancers with an unfavourable prognosis



*GCS : Groupement de Coopération Sanitaire

198

Investigational sites involved

(public hospitals, private clinics, comprehensive cancer centres), including 32 Abroad

787

Active clinical trials

sponsored by the Unicancer network

RESEARCH IN THE UNICANCER NETWORK

- The Unicancer Research Network brings together **the 18 FCCCs**, two affiliated members and the Research Department of the Federation.

As major player in cancer research in France and internationally, Unicancer benefits from the strength of a **dynamic, mobilised and pioneering network**.

15%

of the **Patients**
treated in the FCCCs are
included in a clinical trial

31 Active International Trials

7 Active Countries
outside of France

101 Recruiting Sites
outside of France

INTERNATIONAL: A FORWARD-LOOKING PRIORITY


Unicancer teams initiate and maintain collaborations with research actors at the **international level**.

Unicancer is the local representative of the EORTC in France since 2009.

In this way, we contribute to changing practices and promoting **French excellence** outside France.



This European grouping for the benefit of prostate cancer research has the ambition to conduct comparative trials in Europe to evaluate new treatments. By filling the “numerical gap” in phase III clinical trials, they are making a significant contribution to research and best practice in the treatment of genitourinary cancer. Many results have already been presented at conferences such as ESMO and ASCO.



+89⁰⁰⁰
Samples
stored

UNICANCER OPENS ITS DATA TO RESEARCH

In order to **accelerate the development of knowledge in oncology and to increase the interfaces between basic and clinical research (translational research)**, Unicancer Research provides researchers and clinicians from all institutions with access to data for their projects of interest.

In addition, the numerous ancillary research studies carried out in conjunction with clinical trials have enabled Unicancer to build up a collection of biological samples that can be associated with clinical data and thus allow reuse for research purposes, while respecting the current regulations.



215⁰⁰⁰
Aliquots

AN AMBITIOUS DATA STRATEGY

FOCUS ON FLAGSHIP HEALTH DATA PROGRAMMES



+96000
Cases
Selected



ESMÉ is a unique real-life data collection and analysis system that centralises data on the management of patients with breast, lung and ovarian cancer in France.

unicancer



we share is a research infrastructure supported by future investment programmes dedicated to promoting and facilitating the integration of social and human sciences in cancer research, by pooling resources and skills.


ODH is the first French reference platform developed to accelerate the production and exploitation of quality real-life data. As true drug observatory, ODH should make it possible to characterise the use of therapeutic innovations in oncology.

O N C O

▶ A T A

■ H U B

THE PATIENT AT THE HEART OF OUR ACTIONS



canto CANcer TOxicities is a study that aims to identify the long-term toxic effects of breast cancer treatments in order to improve the quality of life of women during and after cancer.



MyPeBS is an international study coordinated by Unicancer, funded by the European Union, evaluating a new breast cancer screening strategy based on each woman's individual risk of developing the disease.

A total of 85,000 volunteer women aged between 40 and 70 who have never had breast cancer are expected to participate in the recruiting countries: France, Italy, Israel, Belgium, UK, Spain.

www.mypebs.eu

12000
Women
enrolled



827 Partners
Recruiting
Countries

We maintain close and lasting partnerships with the Ligue contre le cancer and the Fondation ARC, two non-profit organisations working organisations working for cancer research.







ACCELERATE RESEARCH AGAINST CANCER.
IMPROVE DIAGNOSTIC AND THERAPEUTIC METHODS.



101, rue de Tolbiac
75654 Paris Cedex 13
Tél. 01 44 23 04 04
unicancer@unicancer.fr

contact@recherche.unicancer.fr